Genitourinary Cancers

Genitourinary cancers are malignant neoplasms of the urinary tract and male genital organs, including prostate, bladder, kidney, and testicular cancer. They span a wide range of behaviors, from indolent prostate tumors often managed by active monitoring to chemosensitive testicular cancers and immune-responsive kidney and bladder cancers, making them a diverse group within site-specific oncology.

Definition

Genitourinary cancers are malignant tumors of the urogenital system, comprising cancers of the prostate, bladder and urinary tract, kidney, testis, and related organs, each with distinct epidemiology, natural history, and treatment.

Scope

This topic provides an overview of the principal genitourinary cancers, their epidemiology, the role of diagnosis and risk stratification (including imaging and biomarkers), and the broad principles of management across the spectrum from active surveillance to systemic therapy. It is a reference orientation to a heterogeneous group of diseases and their evidence base, not individualized clinical advice.

Core questions

• How do the major genitourinary cancers differ in natural history and aggressiveness?
• When is active surveillance appropriate, as in some localized prostate cancers?
• How do imaging and biomarkers refine diagnosis and risk stratification?
• How have targeted and immune therapies changed treatment of kidney and bladder cancer?

Key concepts

• Prostate cancer and active surveillance
• Bladder and upper-tract urothelial cancer
• Renal-cell carcinoma
• Testicular germ-cell tumors
• Risk stratification (PSA, imaging, grade and stage)
• Targeted therapy and immunotherapy in GU cancers

Mechanisms

The genitourinary cancers are biologically diverse. Prostate cancers range from indolent, slow-growing tumors to aggressive disease, which is why risk stratification and, for low-risk disease, active monitoring are central (Hamdy et al., 2016). Renal-cell carcinoma is often driven by pathways amenable to targeted agents and is immune-responsive (Hudes et al., 2007), and urothelial and other GU cancers have shown sensitivity to immune checkpoint blockade, building on early demonstrations of anti-PD-L1 activity across tumor types (Brahmer et al., 2012). Improved imaging, particularly multiparametric MRI in the prostate, has refined how these tumors are detected and characterized (Ahmed et al., 2017).

Clinical relevance

Genitourinary cancers illustrate the breadth of oncology within a single organ system, from cancers where less treatment (active surveillance) can be appropriate to highly treatable germ-cell tumors and immune-responsive kidney and bladder cancers. This entry describes that spectrum and its evidence; it does not provide individualized diagnostic or treatment recommendations.

Epidemiology

Prostate cancer is one of the most commonly diagnosed cancers in men worldwide, and bladder, kidney, and testicular cancers add substantial burden, with incidence patterns shaped by age, sex, smoking (notably for bladder cancer), and detection practices such as PSA testing (Bray et al., 2024). Testicular cancer is comparatively uncommon but is concentrated in younger men and is highly curable, while kidney and bladder cancers rise with age.

Evidence & guidelines

Randomized evidence informs the spectrum of management: long-term trial data support active monitoring as one option for localized prostate cancer alongside surgery and radiotherapy (Hamdy et al., 2016), and trials established systemic agents for advanced renal-cell carcinoma (Hudes et al., 2007). Diagnostic studies such as PROMIS support multiparametric MRI in the prostate pathway (Ahmed et al., 2017), and immune checkpoint inhibition, foreshadowed by early anti-PD-L1 trials (Brahmer et al., 2012), is now established in several GU cancers. Guidelines integrate stage, risk, and biomarkers; specifics evolve and should be read in current sources.

History

Genitourinary oncology has been shaped by debates over screening and overtreatment, especially in prostate cancer, where widespread PSA testing detected many indolent tumors and motivated active surveillance and trials comparing treatment with monitoring (Hamdy et al., 2016). Testicular cancer became a landmark success of curative cisplatin-based chemotherapy, and kidney and bladder cancers were transformed first by targeted therapy and then by immune checkpoint inhibition (Hudes et al., 2007; Brahmer et al., 2012).

Debates

Prostate cancer screening and the risk of overtreatment

PSA-based detection finds many slow-growing prostate cancers that may never cause harm, so balancing early detection against overdiagnosis and overtreatment, and choosing active surveillance versus immediate treatment, remains a central and contested question.

Seminal works

• hamdy-2016
• ahmed-2017
• hudes-2007
• brahmer-2012

Frequently asked questions

Which cancers are considered genitourinary cancers?

They include cancers of the prostate, bladder and urinary tract, kidney, and testis, among other urogenital organs; these are grouped together because they affect the urinary and male reproductive systems, though their biology and treatment differ widely.

Why is active surveillance used in some prostate cancers?

Many localized prostate cancers grow slowly and may never cause harm, so for selected low-risk disease, monitoring with the option to treat later can avoid the harms of immediate treatment; long-term trial evidence supports this as one reasonable option.